NRSN Stock Analysis: Buy, Sell, or Hold?
NRSN - NeuroSense Therapeutics Ltd. Ordinary Shares
$0.70
-0.04 (-4.79%)
▼
5d:
-6.87%
30d:
-17.73%
90d:
-13.71%
HOLD
LOW Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: Jun 30, 2026
14d
Get Alerted When NRSN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NRSN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: NRSN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: NRSN is currently trading at $0.70, which is considered oversold relative to its 30-day fair value range of $0.75 to $0.85.
Technical Outlook: Technically, NRSN is in a downtrend. The price is currently testing key support at $0.73. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.50 (+784.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NRSN is in a downtrend. The price is currently testing key support at $0.73. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.50 (+784.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.75 -
$0.85
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.8%)
- BULLISH: Trading 784.1% below Wall St target ($6.50)
- CAUTION: Recommendation downgraded due to -6.9% 5-day decline
Trading Range Analysis
30-Day Trading Range
$0.75 -
$0.85
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.73
Resistance Level
$0.93
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.90
Wall Street Target
$6.50
(+784.1%)
Share & Embed Analysis
Last updated: June 15, 2026 10:41 AM ET
Data refreshes hourly during market hours. Next update: 11:41 AM
Data refreshes hourly during market hours. Next update: 11:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NRSN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 62 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 60 HOLD |
